BAGANBAZAR GRAPHEXPLORE · ANALYZE · GROW
Theme
LiveDesk
WorldMarvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial SiteWorldBest of cartoons, October 20, 2026WorldPatterson hits 16th first-class tonWorld‘Uncomfortable’: Fremantle captain Alex Pearce speaks out on Woodside sponsorshipWorldBob Woodward reveals "dream source" in memoir, "Secrets," out next month
World/Source-attributed reporting
World DESK

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the […]

Published Oct 19, 2026 · 7:00 AMOriginal source: Financial Post4 reads
CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the […]
ORIGINAL SOURCE

Financial Post

This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.

Read at original outlet ↗
RELATED COVERAGE

More from this desk.